Personalis, INC

Personalis, Inc. announced a definitive agreement to merge with Tempus AI, Inc. in a stock-for-stock transaction, with specific terms regarding stock consideration and potential cash payouts.

Tempus AI announces definitive agreement to acquire Personalis for $1.5 billion, aiming to integrate Personalis's MRD technology into its AI-enabled precision oncology platform.

Personalis, Inc. announced expanded Medicare coverage for its NeXT Personal test, now including monitoring treatment response for specific breast cancer types.

Personalis, Inc. stockholders successfully elected directors, ratified auditors, and approved executive compensation at the 2026 annual meeting.

Personalis, Inc. announced expanded Medicare coverage for its NeXT Personal test, now including immunotherapy monitoring for late-stage solid tumors.

Personalis, Inc. announced the appointment of Richard Chen as its new President, effective March 13, 2026, alongside an increase in his compensation and new equity awards.

Personalis, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a 30% revenue increase driven by clinical diagnostic growth, but also reporting substantial net losses and ongoing operational risks, all while navigating a pending acquisition by Tempus AI.

Personalis, Inc. reported a significant 44% year-over-year revenue decline in Q3 2025, primarily driven by reduced Natera volumes and population sequencing, despite strong growth in clinical diagnostic tests and strategic partnership expansions.

Personalis, Inc. reported a 24% decrease in second-quarter 2025 revenue and a widened net loss, driven by a significant decline in enterprise sales from a major customer, despite growth in clinical diagnostic and population sequencing segments.

Personalis, Inc. announces a 6% increase in revenue for Q1 2025, driven by growth in pharma tests and services and population sequencing, while highlighting progress in clinical diagnostics and key partnerships.

Personalis Inc. saw a 41% increase in revenue in Q3 2024, primarily driven by a 96% surge in pharma test revenue, while also securing significant financing.

Personalis Inc. saw a 35% increase in total revenue in the second quarter of 2024, primarily driven by a significant rise in pharma testing revenue.

Personalis, Inc. reported an 18% revenue decrease in 2025, driven by reduced enterprise sales, but strengthened its cash position and secured key Medicare coverage for its cancer diagnostic tests.

Personalis, Inc. announces a 15% increase in revenue for fiscal year 2024, primarily driven by growth in its pharmaceutical testing services.

Personalis, Inc. establishes a 2020 Inducement Plan to grant various equity awards to new employees, aiming to incentivize their contributions and align their interests with the company's success.

Personalis, Inc. announced a definitive agreement to merge with Tempus AI, Inc. in a transaction structured as a two-step merger, with Tempus AI as the acquirer.

Tempus AI announced a definitive agreement to acquire Personalis for $1.5 billion, aiming to enhance its oncology diagnostics and biopharma offerings.

Tempus AI announced its agreement to acquire Personalis, Inc., aiming to integrate genomic data and AI-driven insights.

Tempus AI announced its agreement to acquire Personalis, Inc. for $1.7 billion, aiming to integrate Personalis's ultrasensitive molecular residual disease (MRD) testing into its AI-enabled precision oncology platform.

Tempus AI, Inc. announced its entry into a definitive Agreement and Plan of Merger with Personalis, Inc., outlining the terms of a two-step merger transaction.

Tempus AI announced its definitive agreement to acquire Personalis, Inc. for $1.5 billion, aiming to integrate Personalis's MRD technology into its AI-enabled precision oncology platform.

Personalis, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Personalis, Inc. has scheduled its Annual Meeting of Stockholders for May 16, 2025, to address director elections, auditor ratification, executive compensation, and other business matters.

Personalis, Inc. has filed a definitive proxy statement with the SEC.

Personalis, Inc. has scheduled its Annual Meeting of Stockholders for May 17, 2024, to address key proposals including the election of directors, ratification of the company's accounting firm, and executive compensation.

Tempus AI has entered into a Merger Agreement to acquire all outstanding common stock of Personalis, Inc., with consideration to be paid in Tempus Class A Common Stock or a mix of cash and stock.

Lightspeed Venture Partners entities reported a reduction in their beneficial ownership of Personalis, Inc. following a pro rata in-kind distribution of shares.

Tempus AI increased its beneficial ownership in Personalis, Inc. to 14.3% and amended their commercial agreement to allow for further open market share acquisitions up to 19.99%.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, reporting beneficial ownership of 5,760,627 shares, representing 5.51% of Personalis, Inc.'s common stock.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4,758,091 shares, representing 4.5% of the outstanding common stock of Personis Inc.

Ameriprise Financial, Inc. has reported a 7.1% beneficial ownership stake in Personalis, Inc. common stock, held in the ordinary course of business.

Orin Hirschman and AIGH Capital Management have jointly filed an amended Schedule 13G, disclosing a 3.8% beneficial ownership stake in Personalis, Inc.

T. Rowe Price Investment Management, Inc. has reported a 12.1% beneficial ownership stake in Personalis Inc. as of December 31, 2025.

ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 7 to Schedule 13G, reporting a combined beneficial ownership of 8.14% of Personalis, Inc.'s common stock as of March 31, 2025.